Related coverage linked through entity extraction aliases.
Mar 17, 2026
CAR T-cell therapy demonstrates near-98% response rates in multiple myeloma trials, but only 2.6% of eligible patients receive treatment. Black patients face substantially lower access, with structural and institutional barriers limiting availability of the specialized therapy.
Mar 12, 2026
MajesTEC-9 trial demonstrates teclistamab's superiority over standard care in second-line multiple myeloma treatment, with significant progression-free survival and overall survival benefits supporting earlier use of the BCMA-targeting bispecific antibody.
Feb 28, 2026
New CAR T-cell approaches targeting BCMA and CD19 simultaneously show encouraging early results, while researchers develop control strategies for CAR-T therapies including antibody-drug conjugates.
Feb 27, 2026
Researchers develop ultra-sensitive CAR-T cells targeting CD70 for solid tumors and KRASG12V/HLA-A*02:01-specific CAR-T cells for cancers with KRAS mutations, demonstrating efficacy in preclinical models.
Feb 25, 2026
Cytokinetics launches MYQORZO for obstructive hypertrophic cardiomyopathy following FDA approval, while C4 Therapeutics doses first patient in Phase 2 trial of cemsidomide for relapsed/refractory multiple myeloma.
Feb 24, 2026
New research demonstrates that dexamethasone effectively ameliorates cytokine-release syndrome in CAR T-cell therapy for multiple myeloma while maintaining or enhancing anti-tumor activity and increasing CAR T-cell levels.
Feb 18, 2026
Preclinical and early clinical data show carfilzomib can restore BCMA expression on myeloma cells after CAR T-cell therapy failure, with 6 of 10 patients experiencing renewed clinical responses in a small study.
Feb 19, 2026
Researchers at Washington University in St. Louis have adapted CAR-T immunotherapy to target aggregated amyloid-beta in mice, with transient CAR expression clearing brain plaques. The approach uses CD4+ T cells engineered with receptors based on lecanemab antibody sequences.
